About SuppreMol
SuppreMol is a Healthcare company based in Planegg (Germany) founded in 2002, and was acquired by Baxter in March 2015. Therapeutics for autoimmune diseases are developed by SuppreMol. SuppreMol has raised $70.99 million across 5 funding rounds from investors including Max-Planck-Gesellschaft, Baxter and KfW. Its chief executive, as recorded, is Jose E Almeida. Its focus areas include Life Sciences, Immunotherapy, Antibody and Immunomodulatory.
Company details
SuppreMol was founded in 2002 and is based in Planegg, Germany. Therapeutics targeting autoimmune diseases are developed by the company, with a focus on the biotechnology sector. The lead candidate, SM101, a recombinant soluble human FcγIIB receptor, is advanced for systemic lupus erythematosus treatment. A pipeline is maintained for primary immune thrombocytopenia, rheumatoid arthritis, and additional autoimmune conditions. Operations center on drug development for these indications.
- Headquarters Planegg, Germany
- Stage Acquired
- SectorsHealthcare
- Website suppremol.com
- Social LinkedIn
- Acquired by Baxter (Mar 2015)
- Total Equity Funding$70.99M (USD)
in 5 rounds
- Latest Funding Round$20.57M (USD), Series D
May 2013
- InvestorsMax-Planck-Gesellschaft
& 7 more
- Acquired byBaxter
(Mar 2015)
Funding Insights of SuppreMol
SuppreMol has successfully raised a total of $70.99M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $20.57 million completed in May 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $70.99M
- Total Rounds 5
- Last Round Series D β $20.57M
- Investors Count 7
All 5 funding rounds of SuppreMol with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2013 | $20.57M | Series D | β | β | |
| Dec 2010 | $20.25M | Series C | β | β | |
| Jul 2008 | $25.02M | Series B | β | β | |
| May 2006 | $5.15M | Series A | β | β | |
| Nov 2005 | Debt – Conventional | β | β |
8 investors in total: 8 institutional.
Investors in SuppreMol
SuppreMol has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Max-Planck-Gesellschaft, Baxter and KfW.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC Firm funding companies in Europe | mig.ag | Munich, Germany | ||
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe | biomedvc.com | Basel, Switzerland | ||
High-tech industries are targeted for investments by Bayern Kapital. | bayernkapital.de | Landshut, Germany | ||
Consumer and SME loans are provided across Germany. | 1948 | kfw.de | Frankfurt Am Main, Germany | |
Ombudsman services for scientific misconduct in research are provided confidentially. | 1948 | mpg.de | Munich, Germany | |
APIs and finished drugs are developed and manufactured in pharmaceuticals. | 1906 | zambon.com | Bresso, Italy | |
| zcube.com | ||||
Biosciences, medication delivery, and renal products are developed and marketed. | 1931 | baxter.com | Deerfield, United States |
Investor details for SuppreMol
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SuppreMol
1 people are tracked at SuppreMol (1 in leadership).
| Name | Role | Group |
|---|---|---|
Jose E Almeida | CEO | Leadership |
Complete people profiles for SuppreMol
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SuppreMol
4 dated milestones of SuppreMol across 13 years, from founding to its latest funding, stage changes and deals.
- Founded SuppreMol is founded.
- Funding First funding round.
- Funding Latest funding round, Series D, of $20.6M.
- Exit Acquired by Baxter.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SuppreMol
SuppreMol was founded in 2002 and raised its 1st funding round 3 years after it was founded.
SuppreMol is headquartered in Planegg, Germany. It is registered at Planegg, Bavaria, Germany.
Jose E Almeida is the CEO of SuppreMol, as recorded in our data.
SuppreMol is a funded company, having raised a total of $70.99M across 5 funding rounds to date.
SuppreMol was founded in 2002 and is based in Planegg, Germany. Therapeutics targeting autoimmune diseases are developed by the company, with a focus on the biotechnology sector. The lead candidate, SM101, a recombinant soluble human FcΞ³IIB receptor, is advanced for systemic lupus erythematosus treatment. A pipeline is maintained for primary immune thrombocytopenia, rheumatoid arthritis, and additional autoimmune conditions. Operations center on drug development for these indications.
SuppreMol has 8 investors. Key investors include Max-Planck-Gesellschaft, Baxter, KfW, Zambon Pharma, and MIG Capital.
Yes. SuppreMol was acquired by Baxter in March 2015.